Table 1.

Examples of theranostic pairs.

Class	Diagnostic Agent	Therapeutic Agent	Target	Disease
Transporter	[123I]I−	[131I]I−	NIS (SLC5A5)	Differentiated thyroid cancer, hyperthyroidism
	[123I]MIBG, [124I]MIBG, [18F]MFBG	[131I]I-MIBG	NET (SLC6A2)	Neuroendocrine tumors, including neuroblastoma, pheochromocytomas, paragangliomas, medullary thyroid carcinoma
Cell-surface receptor	[68Ga]Ga-DOTATATE, [68Ga]Ga-DOTATOC, [68Ga]Ga-DOTANOC	[111In]In-pentetreotide, [177Lu]Lu-DOTATATE (LUTATHERA®), [90Y]Y-DOTATATE, [225Ac]Ac-DOTATATE, [177Lu]Lu-DOTATOC, [90Y]Y-DOTATOC, [225Ac]Ac-DOTATOC, [212Pb]Pb-DOTAMTATE	SSTRs	Neuroendocrine tumors, mostly gastroenteropancreatic tumor (GEP-NET)
Cell-surface protein	[123I]MIP-1072, [123I]MIP-1095, [68Ga]Ga-PSMA-11, [68Ga]Ga-PSMA-I&T, [68Ga]Ga-PSMA-617	[131I]I-MIP-1095, [177Lu]Lu-PSMA-I&T, [177Lu]Lu-PSMA-617, [225Ac]Ac-PSMA-617	PSMA	Metastatic prostate cancer
	[89Zr]Zr-trastuzumab, [68Ga]Ga-NOTA-HER2	[177Lu]Lu-trastuzumab and derivatives, [131I]GMIB-anti-HER2-VHH1	HER2	Breast, ovarian and gastric cancer